Overview
Peptides in South Korea are handled entirely through pharmaceutical law rather than a separate 'peptide' or 'research chemical' category: any peptide intended for injection or human use is treated as a drug (의약품) under the Pharmaceutical Affairs Act (약사법), enforced by the Ministry of Food and Drug Safety (MFDS). Approved peptide medicines such as GLP-1 weight-loss drugs (semaglutide/Wegovy, liraglutide/Saxenda) and growth hormone products are prescription-only and may be dispensed only through licensed doctors and pharmacies, while peptides with no MFDS product licence (e.g. BPC-157 and TB-500 style 'research' peptides) cannot lawfully be imported, sold, or advertised. Importing drugs requires MFDS import-business filing plus a per-item licence, and MFDS has since October 2024 asked the Korea Customs Service to block personal overseas purchases of GLP-1 obesity drugs, treating self-use importation as illegal importation. Enforcement is active, with MFDS cyber-investigation sweeps of online listings and takedown/blocking requests, so the practical position is heavily restricted rather than merely gray.
Key Points
- MFDS classifies GLP-1 weight-loss peptides such as Wegovy (semaglutide) and Saxenda (liraglutide) as prescription-only medicines (전문의약품) that must be prescribed by a physician and dispensed with pharmacist counselling, and it has publicly told the public not to obtain them via overseas online direct purchase or person-to-person transactions. [1]
- Under Article 42 of the Pharmaceutical Affairs Act, anyone importing drugs as a business must file as an importer with the Minister of Food and Drug Safety and obtain a licence or file a notification for each individual product item, which is the mechanism that makes unlicensed peptide products unlawful to bring into the country commercially. [2]
- Selling, or storing/displaying for sale, drugs that were imported in violation of Article 42(1) is punishable under Article 93(1)(10) of the Pharmaceutical Affairs Act by up to 5 years' imprisonment or a fine of up to 50 million won. [3]
- In October 2024 MFDS notified the Korea Customs Service of named obesity drugs (Wegovy, Mounjaro, Saxenda) as 'harmful drugs' to be stopped at the border, taking the position that even buying such drugs abroad for one's own use constitutes illegal importation under the Pharmaceutical Affairs Act, with customs reporting over 8,000 items flagged for clearance blocking. [4]
- Korean customs practice allows a limited personal-use exemption from import requirement-confirmation for medicines totalling no more than 6 bottles (or a three-month supply per the dosage instructions) and under US$150 in value, which is the narrow channel personal importers commonly attempt to use. [5]
- MFDS's cyber investigation team ran a one-month intensive crackdown from 15 October to 14 November 2024 and detected and blocked 359 cases of illegal online sale or advertising of obesity drugs, with GLP-1 products (Wegovy and Saxenda) accounting for about 42% (150 cases) of the total. [6]
- MFDS regulates synthetic peptides as pharmaceutical products and has issued formal quality-evaluation guidance for low-molecular-weight synthetic peptide drugs, confirming that peptide substances intended for therapeutic use fall inside the licensed-medicine framework rather than outside it. [7]
- Human growth hormone products are likewise prescription medicines for specific indications, and MFDS has issued public warnings against their off-label misuse as 'height-increasing injections' and announced continued crackdowns on exaggerated advertising. [8]
- No South Korea-specific statute, MFDS notice, or scheduling entry naming BPC-157 or TB-500 was located in these searches; the conclusion that such unapproved research peptides are unlawful to import or sell is an inference from the general unlicensed-drug provisions of the Pharmaceutical Affairs Act rather than from a peptide-specific Korean source. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)